- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Mark Eaton
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marco Herold
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sant-Rayn Pasricha
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Boosting the efficacy of immunotherapy in lung cancer
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Discoveries in red blood cell production and function
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Cancer drugs show promise in preventing malaria
1 April 2020
A potential new approach for preventing malaria is on the horizon with the discovery that drugs currently used to kill cancer cells can also kill malaria-infected liver cells.
A team from the Walter and Eliza Hall Institute showed in preclinical models that anti-cancer drugs can kill Plasmodium-infected liver cells, while leaving other cells unharmed.
Liver infection is the first stage of malaria parasite infection in humans following a mosquito bite. The parasites’ ability to hide and multiply in the liver before causing malaria in the bloodstream is a significant target for effective malaria control.
The new approach outsmarts the malaria parasite by causing infected cells to die, while also boosting host immunity and decreasing the chance of parasites becoming drug resistant.
The research was led by infectious disease researchers Associate Professor Justin Boddey, Dr Greg Ebert and Professor Marc Pellegrini at the Walter and Eliza Hall Institute, and was published in Cell Reports.
At a glance
- Institute researchers have harnessed anti-cancer drugs to combat malaria.
- Rather than attacking the parasite, the drugs kill Plasmodium-infected liver cells and thwart the parasite’s ability to develop drug resistance.
- The drugs were successful in clearing 95 per cent of infection and led to an increase in host immunity.
Targeting parasite-infected cells
Plasmodium parasites are estimated to infect more than 200 million people each year and cause 619,000 malaria-related deaths annually. Shortly after infecting the host, parasites set about exploiting their new environment in order to survive and spread. The first stop in this journey is the liver, where the parasites hide and multiply.
Associate Professor Boddey said the team revealed that Plasmodium parasites are able to survive and multiply in the liver by hijacking certain parts of the cell death machinery to stop their host cells from dying.
“A particular form of cell death called apoptosis, initiated by the extrinsic signaling pathway, has evolved to defend us against infection by parasites, bacteria and viruses, and is triggered as a way of fighting the infection,” he said.
“We showed that malaria parasites hijack this pathway, increasing production of proteins called cIAPs (cellular inhibitors of apoptosis proteins). This tricks the body into keeping the infected cells alive and allows malaria parasites to happily hide away, multiplying in the liver.”
Pellegrini and Dr Greg Ebert.
Dr Ebert said the team was excited to discover that cancer drugs called IAP inhibitors, initially developed for cancer therapy, could be repurposed to override the parasite’s cunning tactics and trigger the death of infected liver cells.
“Using IAP inhibitors, we were able to preferentially target parasite-infected liver cells and eliminate more than 95 per cent of Plasmodium infection.”
“The approach we took drew lessons from previous research, where we successfully harnessed the same strategy to eliminate all traces of liver-specific hepatitis B virus infection in preclinical models.
“But Plasmodium infection is different, you only need one parasite to complete the liver phase to infect the bloodstream and initiate malaria. So our challenge now is to stop the very small number of remaining parasites that are still entering the blood stream,” Dr Ebert said.
Boosting immunity, preventing resistance
Malaria’s infamous ability to evade the immune system and evolve drug-resistance are among the major hurdles that make it such a difficult disease to eliminate.
Professor Pellegrini said the new study showed promise in both boosting host immunity and decreasing the potential for drug resistance.
“By targeting the host cell, the parasite isn’t under selective pressure to develop resistance to the drug – this is a big plus.”
“In addition, by causing infected cells to undergo programmed death, the parasite is no longer able to hide undetected in the liver. As a result, we observed that the immune system was reacting to the infection by mounting a T-cell response. This boosted host immunity and changed the course of a subsequent infection for the better,” Professor Pellegrini said.
Key to malaria elimination
Associate Professor Boddey said the research was an exciting proof of concept that host-based therapy could eliminate malaria parasites, and the next steps would be to try IAP inhibitors in combination with different other drugs in order to examine whether they could completely clear malaria infection of the liver in preclinical models.
He said targeting parasite-infected liver cells could be particularly useful in areas, such as the Asia-Pacific, where Plasmodium vivax (P. vivax) is a significant problem.
“P. vivax is especially insidious because it can lay dormant in the liver for months, causing patients to become sick again and again whilst also allowing further transmission in the community,” he said.
“The only drugs available to kill dormant P. vivax infections can be very toxic to some people.
"New drugs that kill P. vivax at the liver stage of infection are very important for preventing relapse and giving us a real chance at eliminating malaria.”
The research was supported by the Australian National Health and Medical Research Council, Human Frontiers Science Program (US), Sylvia & Charles Viertel Charitable Foundation and the Victorian Government.
WEHI.TV: How malaria infects humans
Media enquiries
M: +61 475 751 811
E: communityrelations@wehi.edu.au
Super Content:
The institute's malaria research team is homing in on a new target for malaria treatment
Visualisation of the parasite infection inside a pregnant female mosquito.
We are a member of the Asia Pacific Malaria Elimination Network (APMEN), an international collaborative network working towards eliminating malaria in the Asia-Pacific region.
We have developed the first malaria vaccine that can be tailored to match many different strains of malaria.
Our biomedical animation team explains the discoveries made by scientists through 3D animation.
Check out our YouTube channel: latest WEHI.TV animations, videos of our public lectures, news releases and staff profiles.
Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate.